Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

61. Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism

Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism 29971237 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Actionable Metabolic Pathways in Heart Failure and Cancer-Lessons From Cancer Cell Metabolism. 71 10.3389/fcvm.2018.00071 Recent advances in cancer cell metabolism provide unprecedented opportunities for a new understanding of heart metabolism and may offer new approaches for the treatment of heart failure (...) . Key questions driving the cancer field to understand how tumor cells reprogram metabolism and to benefit tumorigenesis are also applicable to the heart. Recent experimental and conceptual advances in cancer cell metabolism provide the cardiovascular field with the unique opportunity to target metabolism. This review compares cancer cell metabolism and cardiac metabolism with an emphasis on strategies of cellular adaptation, and how to exploit metabolic changes for therapeutic benefit. Karlstaedt

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

62. Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines

Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines 29916560 2018 11 29 2055-5822 5 5 2018 10 ESC heart failure ESC Heart Fail Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. 745-754 10.1002/ehf2.12307 Heart failure (HF) is a complex disease, almost as common in women as in men. Nonetheless, HF clinical presentation, prognosis, and aetiology vary (...) by sex. This review summarizes the current state of sex-sensitive issues related to HF drugs included in treatment guidelines and suggests future directions for improved care. Heart failure presentation differs between female and male patients: females more often show with hypertensive aetiology and the preserved ejection fraction phenotype, while men more often show ischaemic aetiology and the reduced ejection fraction phenotype. Yet the HF clinical guidelines in Europe, the United States

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

63. Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure

Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure 29901286 2018 11 29 2055-5822 5 5 2018 10 ESC heart failure ESC Heart Fail Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure. 858-863 10.1002/ehf2.12299 The aim of this study was to identify echocardiographic predictors of improved or worsening renal function during intravenous diuresis for decompensated heart failure (...) . Secondary aim included defining the incidence and clinical risk factors for acute changes in renal function with decongestion. A retrospective review of 363 patients admitted to a single centre for decompensated heart failure who underwent intravenous diuresis and transthoracic echocardiography was conducted. Clinical, echocardiographic, and renal function data were retrospectively collected. A multinomial logistic regression model was created to determine relative risk ratios for improved renal

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

64. Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk

Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk 29893487 2018 11 29 2055-5822 5 5 2018 10 ESC heart failure ESC Heart Fail Prospective assessment of combined handgrip strength and Mini-Cog identifies hospitalized heart failure patients at increased post-hospitalization risk. 948-952 10.1002/ehf2.12300 The utility of combined assessment of both frailty and cognitive impairment (...) in hospitalized heart failure (HF) patients for incremental post-discharge risk stratification, using handgrip strength and Mini-Cog as feasible representative parameters, was investigated. A prospective, single-centre cohort study of older adults (age ≥65) hospitalized for HF being discharged to home was performed. Pre-discharge, grip strength was assessed using a dynamometer (Jamar hydrolic hand dynamometer, Lafayette Instruments, Lafayette, IN, USA) and was defined as weak if the maximal value was below

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

65. Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure

Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure 29893475 2018 11 29 2055-5822 5 5 2018 10 ESC heart failure ESC Heart Fail Daily non-invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure. 780-787 10.1002/ehf2.12303 Patients with advanced systolic chronic heart failure frequently suffer from progressive functional (...) mitral regurgitation. We report our initial experience in patients with an implanted pulmonary artery pressure (PAP) sensor, who developed severe mitral regurgitation, which was treated with the MitraClip system. We non-invasively compared changes in PAP values in patients after MitraClip with PAP changes in patients without MitraClip. Among 28 patients with New York Heart Association III heart failure with implanted PAP sensor for haemodynamic telemonitoring from a single centre, four patients (age

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

66. Heart Failure.

Heart Failure. Heart failure affects more than 6 million people in the United States and incurs a heavy toll in morbidity, mortality, and health care costs. It frequently coexists with other important disorders, including hypertension, coronary artery disease, diabetes, and obesity. Decades of clinical trials have shown that several medications and interventions are effective for improving outcomes; however, mortality and hospitalization rates remain high. More recently, additional medications (...) and devices have shown promise in reducing the health burden of heart failure.

Annals of Internal Medicine2018

67. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis

Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis 29799995 2018 05 25 2168-6114 2018 May 21 JAMA internal medicine JAMA Intern Med Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. 10.1001/jamainternmed.2018.0850 Treatment with aldosterone antagonists is recommended (...) and has been shown to have beneficial effects in patients with ST-segment elevation myocardial infarction (STEMI) and left ventricular ejection fraction (LVEF) less than 40%. However, the role of aldosterone antagonists in patients with ejection fraction greater than 40% or without congestive heart failure is not well known. To perform a systematic review and meta-analysis using standard techniques to determine the role of therapy with aldosterone antagonists in this patient population. PubMed, Embase

EvidenceUpdates2018

68. His Bundle Pacing: A New Frontier in the Treatment of Heart Failure

His Bundle Pacing: A New Frontier in the Treatment of Heart Failure 29967682 2018 11 14 2050-3369 7 2 2018 Jun Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev His Bundle Pacing: A New Frontier in the Treatment of Heart Failure. 103-110 10.15420/aer.2018.6.2 Biventricular pacing has revolutionised the treatment of heart failure in patients with sinus rhythm and left bundle branch block; however, left ventricular-lead placement is not always technically possible. Furthermore (...) , biventricular pacing does not fully normalise ventricular activation and, therefore, the ventricular resynchronisation is imperfect. Right ventricular pacing for bradycardia may cause or worsen heart failure in some patients by causing dyssynchronous ventricular activation. His bundle pacing activates the ventricles via the native His-Purkinje system, resulting in true physiological pacing, and, therefore, is a promising alternate site for pacing in bradycardia and traditional CRT indications in cases where

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

69. Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?

Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? 29967680 2018 11 14 2050-3369 7 2 2018 Jun Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines? 91-94 10.15420/aer.2018.17.2 AF in patients with heart failure and reduced ejection (...) fraction (HFrEF) is common and is associated with an increased risk of stroke, heart failure hospitalisation and all-cause mortality. Rhythm control of AF in this population has been traditionally limited to the use of antiarrhythmic drugs. Clinical trials assessing superiority of pharmacological rhythm control over rate control have been largely disappointing. Catheter ablation has emerged as a viable alternative to pharmacological rhythm control in symptomatic AF and has enjoyed significant

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

70. Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All

Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All 29967679 2018 11 14 2050-3369 7 2 2018 Jun Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All. 84-90 10.15420/aer.2018.11.3 Atrial fibrillation (AF) is common in patients with heart failure and is associated with poorer clinical outcomes compared with patients with heart failure alone. Recent evidence has (...) challenged previous treatment paradigms in which rate control was considered equivalent to rhythm control in this population. Catheter ablation has emerged as a safe and effective treatment strategy in selected patients and overcomes the issues of limited efficacy and drug toxicities associated with pharmacological rhythm control. Numerous studies have explored the benefits of catheter ablation in patients with heart failure, but these have included heterogeneous patient cohorts and variable ablation

Arrhythmia & electrophysiology review2018 Full Text: Link to full Text with Trip Pro

71. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Marvin A. Konstam , Michael S (...) . Kiernan Daniel Bernstein Biykem Bozkurt Miriam Jacob Navin K. Kapur Robb D. Kociol Eldrin F. Lewis Mandeep R. Mehra Francis D. Pagani Amish N. Raval Carey Ward Jump to Abstract Background and Purpose: The diverse causes of right-sided heart failure (RHF) include, among others, primary cardiomyopathies with right ventricular (RV) involvement, RV ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading

American Heart Association2018

72. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis.

Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. OBJECTIVE: To assess the diagnostic accuracy of point-of-care natriuretic peptide tests in patients with chronic heart failure, with a focus on the ambulatory care setting. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Ovid Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database (...) if reported data were insufficient to construct 2×2 tables. No language restrictions were applied. RESULTS: 42 publications of 39 individual studies met the inclusion criteria and 40 publications of 37 studies were included in the analysis. Of the 37 studies, 30 evaluated BNP point-of-care testing and seven evaluated NTproBNP testing. 15 studies were done in ambulatory care settings in populations with a low prevalence of chronic heart failure. Five studies were done in primary care. At thresholds >100

BMJ2018 Full Text: Link to full Text with Trip Pro

73. Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN 29767459 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST (...) -DN. 592-602 10.1002/ehf2.12292 Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium-free, non-absorbed potassium binder approved for HK treatment. We retrospectively evaluated patiromer's long-term safety and efficacy in HF patients from AMETHYST-DN. Patients with Type 2 diabetes, CKD, and HK [baseline serum potassium >5.0-5.5 mmol/L

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

74. Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a before‐and‐after study

Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a before‐and‐after study 29757497 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Effectiveness of a transition plan at discharge of patients hospitalized with heart failure: a before-and-after study. 657-667 10.1002/ehf2.12295 We evaluated the effectiveness of a multidisciplinary transition plan to reduce early readmission among heart failure patients. We conducted a before (...) -and-after study in a tertiary internal medicine department, comparing 3 years of retrospective data (pre-intervention) and 13 months of prospective data (intervention period). Intervention was the introduction in 2013 of a transition plan performed by a multidisciplinary team. We included all consecutive patients hospitalized with symptomatic heart failure and discharged to home. The outcomes were the fraction of days spent in hospital because of readmission, based on the sum of all days spent

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

75. Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis

Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis 29745463 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all-comer population of patients with heart failure: a retrospective analysis. 630-641 10.1002/ehf2.12296 Aetiology of heart failure (HF) often remains (...) obscure. We therefore evaluated the usefulness of a combined diagnostic approach including cardiac magnetic resonance imaging (CMRI) and endomyocardial biopsy (EMB) to assess the cause of unexplained cardiomyopathy underlying HF. We retrospectively investigated 100 consecutive patients (36% women, mean age 53.6 ± 18.8 years) presenting with unexplained cardiomyopathy (HF with reduced ejection fraction or left ventricular hypertrophy; excluding ischaemic and valvular heart disease; left ventricular

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

76. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure

Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure 1 Translation of the executive summary of the assessment of potential Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz (Version 1.0; Status: 8 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text (...) is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. E15-04 Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure 1 Executive summary of the assessment of potential E15-04 Version 1.0 PA pressure monitoring in heart failure 8 January 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

77. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04

Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04 1 Translation of the executive summary of the addendum Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz – Addendum zum Auftrag E15-04 (Version 1.0; Status: 20 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers (...) . However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. E16-02 Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failureAddendum to Commission E15-04 1 Executive summary of Addendum E16-02 Version 1.0 PA pressure monitoring in heart failure 20 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

78. Palliative care in the outpatient setting for patients with heart failure or advanced lung disease

Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Lavenberg JG, Umscheid, CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Lavenberg JG, Umscheid, CA. Palliative care in the outpatient setting for patients with heart failure or advanced lung disease. Philadelphia: Center for Evidence-based Practice (CEP). 2018 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Heart Failure; Humans; Lung Diseases; Outpatients; Palliative Care; Quality of Life Language Published English Country of organisation United States English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2018

79. Ivabradine (Lancora) - chronic heart failure

Ivabradine (Lancora) - chronic heart failure Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated

Health Canada - Drug and Health Product Register2018

80. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality

NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality 29242350 2018 04 17 1524-4539 137 16 2018 Apr 17 Circulation Circulation NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided (...) Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). 1671-1683 10.1161/CIRCULATIONAHA.117.029882 The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), with only limited success. The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients with acute decompensated HF using a relative NT-proBNP target has not been investigated. This study aimed to assess

EvidenceUpdates2018